Department of Medicine and Therapeutics, and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, NT, Hong Kong, China.
J Am Soc Nephrol. 2011 Aug;22(8):1462-74. doi: 10.1681/ASN.2010121308. Epub 2011 Jul 22.
TGF-β/Smad3 signaling promotes fibrosis, but the development of therapeutic interventions involving this pathway will require the identification and ultimate targeting of downstream fibrosis-specific genes. In this study, using a microRNA microarray and real-time PCR, wild-type mice had reduced expression of miR-29 along with the development of progressive renal fibrosis in obstructive nephropathy. In contrast, Smad3 knockout mice had increased expression of miR-29 along with the absence of renal fibrosis in the same model of obstruction. In cultured fibroblasts and tubular epithelial cells, Smad3 mediated TGF-β(1)-induced downregulation of miR-29 by binding to the promoter of miR-29. Furthermore, miR-29 acted as a downstream inhibitor and therapeutic microRNA for TGF-β/Smad3-mediated fibrosis. In vitro, overexpression of miR-29b inhibited, but knockdown of miR-29 enhanced, TGF-β(1)-induced expression of collagens I and III by renal tubular cells. Ultrasound-mediated gene delivery of miR-29b either before or after established obstructive nephropathy blocked progressive renal fibrosis. In conclusion, miR-29 is a downstream inhibitor of TGF-β/Smad3-mediated fibrosis and may have therapeutic potential for diseases involving fibrosis.
TGF-β/Smad3 信号通路促进纤维化,但是开发涉及该通路的治疗干预措施需要鉴定和最终靶向纤维化特异性基因。在这项研究中,通过 microRNA 微阵列和实时 PCR 分析,在梗阻性肾病进展性肾纤维化发生时,野生型小鼠的 miR-29 表达降低。相比之下,在同样的梗阻模型中,Smad3 基因敲除小鼠的 miR-29 表达增加,同时没有发生肾纤维化。在培养的成纤维细胞和肾小管上皮细胞中,Smad3 通过结合 miR-29 启动子来介导 TGF-β(1)诱导的 miR-29 下调。此外,miR-29 作为 TGF-β/Smad3 介导纤维化的下游抑制剂和治疗性 microRNA。在体外,miR-29b 的过表达抑制了 TGF-β(1)诱导的肾肾小管细胞中胶原 I 和胶原 III 的表达,但 miR-29 的敲低增强了这种表达。在建立梗阻性肾病之前或之后,超声介导的 miR-29b 基因传递阻断了进行性肾纤维化。总之,miR-29 是 TGF-β/Smad3 介导纤维化的下游抑制剂,可能具有涉及纤维化的疾病的治疗潜力。